The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.
“As a convenient once-daily pill, orforglipron may provide a new option”—Lilly's oral GLP-1 agent showed up to 7.9% weight loss and HbA1c reductions in phase III diabetes trial.
Mavacamten's phase III trial for nonobstructive hypertrophic cardiomyopathy does not show significant improvement in functional capacity or symptoms, reflecting challenges in less severe populations. Bristol Myers Squibb plans to present full data at a future scientific meeting.
Researchers found most FDA-authorized COVID-19 treatments were not linked to serious adverse events, though risks may rise with tocilizumab or convalescent plasma in specific patients.
Results from a trial reveal that Eli Lilly's tirzepatide, a weight loss drug, reduces the risk of heart failure outcomes by 38% compared to a placebo for obese adults, with significant weight loss and improved symptoms. Novo Nordisk's Wegovy also shows promise in reducing heart failure symptoms.
Reuters
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Rezolute Inc has received FDA approval to proceed with its late-stage trial for a new treatment addressing low blood sugar in individuals with congenital hyperinsulinism, with potential U.S. enrollment expected to start in early 2025.
On November 16, 2023, the U.S. Food and Drug Administration (FDA) approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor–positive, HER2-negative locally advanced or m...
March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.
The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.